cpass enzyme-linked immunosorbent assay (elisa) sars-cov-2 neutralization antibody detection kit (GenScript corporation)
90
Structured Review
GenScript corporation
cpass enzyme-linked immunosorbent assay (elisa) sars-cov-2 neutralization antibody detection kit
Cpass Enzyme Linked Immunosorbent Assay (Elisa) Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpass+enzyme-linked+immunosorbent+assay+(elisa)+sars-cov-2+neutralization+antibody+detection+kit/cpass+sars+cov+2+neutralization+antibody+detection+kit/pm40132457-53-0-10
Average 90 stars, based on 1 article reviews
Cpass Enzyme Linked Immunosorbent Assay (Elisa) Sars Cov 2 Neutralization Antibody Detection Kit, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cpass+enzyme-linked+immunosorbent+assay+(elisa)+sars-cov-2+neutralization+antibody+detection+kit/cpass+sars+cov+2+neutralization+antibody+detection+kit/pm40132457-53-0-10
Average 90 stars, based on 1 article reviews
cpass enzyme-linked immunosorbent assay (elisa) sars-cov-2 neutralization antibody detection kit - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Neutralization:Article Title: Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species. Article Snippet: Both, the Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Integrated viral and immune monitoring in a prospective COVID-19 cohort from India. Article Snippet: In this study, we report on longitudinal kinetics of cellular immune subsets following SARS-CoV-2 infection in a cohort of hospitalized individuals and evaluate the interplay of these profiles with infecting viral variants, humoral immunity including neutralizing responses, vaccination history, and clinical outcomes.. A cohort of 121 SARS-CoV-2–infected individuals exhibiting varying disease states were prospectively evaluated for lymphopenic profiles, antiviral humoral responses and infecting viral variants for a period of up to 90 d spanning the period of February 2021 to January 2022 (second and third waves of infection).. A total of 51 participants received at least 1 vaccine dose of indigenous vaccines (Covishield or Covaxin) prior to recruitment. Article Title: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? Article Snippet: To identify the portion of SARS-CoV-2 NABs in relation to all antibodies [%], a blocking enzyme-linked immunosorbent assay ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination. Article Snippet: The presence of antibodies to SARS-Cov-2 spike protein in nasal and oral mucosa, representing the frontline of host defense against COVID-19 infection, has been increasingly recognized as a key player in the acquired immunity.. Here we describe systemic and local antibody responses detected by Dual Path Platform (DPP) SARSCoV-2 IgM/IgG Assay during infection or after COVID-19 vaccine administration.. This rapid point-of-care test differentially detects circulating IgM and IgG antibodies to receptor-binding domain of SARS-CoV-2 spike protein in infected patients with diagnostic sensitivity ranging from 83 to 100 % (depending on the infection stage) at the specificity of 99–100 %. Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Enzyme-linked Immunosorbent Assay:Article Title: Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species. Article Snippet: Both, the Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Integrated viral and immune monitoring in a prospective COVID-19 cohort from India. Article Snippet: In this study, we report on longitudinal kinetics of cellular immune subsets following SARS-CoV-2 infection in a cohort of hospitalized individuals and evaluate the interplay of these profiles with infecting viral variants, humoral immunity including neutralizing responses, vaccination history, and clinical outcomes.. A cohort of 121 SARS-CoV-2–infected individuals exhibiting varying disease states were prospectively evaluated for lymphopenic profiles, antiviral humoral responses and infecting viral variants for a period of up to 90 d spanning the period of February 2021 to January 2022 (second and third waves of infection).. A total of 51 participants received at least 1 vaccine dose of indigenous vaccines (Covishield or Covaxin) prior to recruitment. Article Title: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? Article Snippet: To identify the portion of SARS-CoV-2 NABs in relation to all antibodies [%], a blocking enzyme-linked immunosorbent assay ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination. Article Snippet: The presence of antibodies to SARS-Cov-2 spike protein in nasal and oral mucosa, representing the frontline of host defense against COVID-19 infection, has been increasingly recognized as a key player in the acquired immunity.. Here we describe systemic and local antibody responses detected by Dual Path Platform (DPP) SARSCoV-2 IgM/IgG Assay during infection or after COVID-19 vaccine administration.. This rapid point-of-care test differentially detects circulating IgM and IgG antibodies to receptor-binding domain of SARS-CoV-2 spike protein in infected patients with diagnostic sensitivity ranging from 83 to 100 % (depending on the infection stage) at the specificity of 99–100 %. Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Clinical Proteomics:Article Title: Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species. Article Snippet: Both, the Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Integrated viral and immune monitoring in a prospective COVID-19 cohort from India. Article Snippet: In this study, we report on longitudinal kinetics of cellular immune subsets following SARS-CoV-2 infection in a cohort of hospitalized individuals and evaluate the interplay of these profiles with infecting viral variants, humoral immunity including neutralizing responses, vaccination history, and clinical outcomes.. A cohort of 121 SARS-CoV-2–infected individuals exhibiting varying disease states were prospectively evaluated for lymphopenic profiles, antiviral humoral responses and infecting viral variants for a period of up to 90 d spanning the period of February 2021 to January 2022 (second and third waves of infection).. A total of 51 participants received at least 1 vaccine dose of indigenous vaccines (Covishield or Covaxin) prior to recruitment. Article Title: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? Article Snippet: To identify the portion of SARS-CoV-2 NABs in relation to all antibodies [%], a blocking enzyme-linked immunosorbent assay ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination. Article Snippet: The presence of antibodies to SARS-Cov-2 spike protein in nasal and oral mucosa, representing the frontline of host defense against COVID-19 infection, has been increasingly recognized as a key player in the acquired immunity.. Here we describe systemic and local antibody responses detected by Dual Path Platform (DPP) SARSCoV-2 IgM/IgG Assay during infection or after COVID-19 vaccine administration.. This rapid point-of-care test differentially detects circulating IgM and IgG antibodies to receptor-binding domain of SARS-CoV-2 spike protein in infected patients with diagnostic sensitivity ranging from 83 to 100 % (depending on the infection stage) at the specificity of 99–100 %. Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Functional Assay:Article Title: Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species. Article Snippet: Both, the Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Integrated viral and immune monitoring in a prospective COVID-19 cohort from India. Article Snippet: In this study, we report on longitudinal kinetics of cellular immune subsets following SARS-CoV-2 infection in a cohort of hospitalized individuals and evaluate the interplay of these profiles with infecting viral variants, humoral immunity including neutralizing responses, vaccination history, and clinical outcomes.. A cohort of 121 SARS-CoV-2–infected individuals exhibiting varying disease states were prospectively evaluated for lymphopenic profiles, antiviral humoral responses and infecting viral variants for a period of up to 90 d spanning the period of February 2021 to January 2022 (second and third waves of infection).. A total of 51 participants received at least 1 vaccine dose of indigenous vaccines (Covishield or Covaxin) prior to recruitment. Article Title: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? Article Snippet: To identify the portion of SARS-CoV-2 NABs in relation to all antibodies [%], a blocking enzyme-linked immunosorbent assay ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination. Article Snippet: The presence of antibodies to SARS-Cov-2 spike protein in nasal and oral mucosa, representing the frontline of host defense against COVID-19 infection, has been increasingly recognized as a key player in the acquired immunity.. Here we describe systemic and local antibody responses detected by Dual Path Platform (DPP) SARSCoV-2 IgM/IgG Assay during infection or after COVID-19 vaccine administration.. This rapid point-of-care test differentially detects circulating IgM and IgG antibodies to receptor-binding domain of SARS-CoV-2 spike protein in infected patients with diagnostic sensitivity ranging from 83 to 100 % (depending on the infection stage) at the specificity of 99–100 %. Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Infection:Article Title: Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species. Article Snippet: Both, the Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Integrated viral and immune monitoring in a prospective COVID-19 cohort from India. Article Snippet: In this study, we report on longitudinal kinetics of cellular immune subsets following SARS-CoV-2 infection in a cohort of hospitalized individuals and evaluate the interplay of these profiles with infecting viral variants, humoral immunity including neutralizing responses, vaccination history, and clinical outcomes.. A cohort of 121 SARS-CoV-2–infected individuals exhibiting varying disease states were prospectively evaluated for lymphopenic profiles, antiviral humoral responses and infecting viral variants for a period of up to 90 d spanning the period of February 2021 to January 2022 (second and third waves of infection).. A total of 51 participants received at least 1 vaccine dose of indigenous vaccines (Covishield or Covaxin) prior to recruitment. Article Title: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? Article Snippet: To identify the portion of SARS-CoV-2 NABs in relation to all antibodies [%], a blocking enzyme-linked immunosorbent assay ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination. Article Snippet: The presence of antibodies to SARS-Cov-2 spike protein in nasal and oral mucosa, representing the frontline of host defense against COVID-19 infection, has been increasingly recognized as a key player in the acquired immunity.. Here we describe systemic and local antibody responses detected by Dual Path Platform (DPP) SARSCoV-2 IgM/IgG Assay during infection or after COVID-19 vaccine administration.. This rapid point-of-care test differentially detects circulating IgM and IgG antibodies to receptor-binding domain of SARS-CoV-2 spike protein in infected patients with diagnostic sensitivity ranging from 83 to 100 % (depending on the infection stage) at the specificity of 99–100 %. Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Inhibition:Article Title: Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species. Article Snippet: Both, the Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Integrated viral and immune monitoring in a prospective COVID-19 cohort from India. Article Snippet: In this study, we report on longitudinal kinetics of cellular immune subsets following SARS-CoV-2 infection in a cohort of hospitalized individuals and evaluate the interplay of these profiles with infecting viral variants, humoral immunity including neutralizing responses, vaccination history, and clinical outcomes.. A cohort of 121 SARS-CoV-2–infected individuals exhibiting varying disease states were prospectively evaluated for lymphopenic profiles, antiviral humoral responses and infecting viral variants for a period of up to 90 d spanning the period of February 2021 to January 2022 (second and third waves of infection).. A total of 51 participants received at least 1 vaccine dose of indigenous vaccines (Covishield or Covaxin) prior to recruitment. Article Title: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? Article Snippet: To identify the portion of SARS-CoV-2 NABs in relation to all antibodies [%], a blocking enzyme-linked immunosorbent assay ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination. Article Snippet: The presence of antibodies to SARS-Cov-2 spike protein in nasal and oral mucosa, representing the frontline of host defense against COVID-19 infection, has been increasingly recognized as a key player in the acquired immunity.. Here we describe systemic and local antibody responses detected by Dual Path Platform (DPP) SARSCoV-2 IgM/IgG Assay during infection or after COVID-19 vaccine administration.. This rapid point-of-care test differentially detects circulating IgM and IgG antibodies to receptor-binding domain of SARS-CoV-2 spike protein in infected patients with diagnostic sensitivity ranging from 83 to 100 % (depending on the infection stage) at the specificity of 99–100 %. Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Binding Assay:Article Title: Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species. Article Snippet: Both, the Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Integrated viral and immune monitoring in a prospective COVID-19 cohort from India. Article Snippet: In this study, we report on longitudinal kinetics of cellular immune subsets following SARS-CoV-2 infection in a cohort of hospitalized individuals and evaluate the interplay of these profiles with infecting viral variants, humoral immunity including neutralizing responses, vaccination history, and clinical outcomes.. A cohort of 121 SARS-CoV-2–infected individuals exhibiting varying disease states were prospectively evaluated for lymphopenic profiles, antiviral humoral responses and infecting viral variants for a period of up to 90 d spanning the period of February 2021 to January 2022 (second and third waves of infection).. A total of 51 participants received at least 1 vaccine dose of indigenous vaccines (Covishield or Covaxin) prior to recruitment. Article Title: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? Article Snippet: To identify the portion of SARS-CoV-2 NABs in relation to all antibodies [%], a blocking enzyme-linked immunosorbent assay ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination. Article Snippet: The presence of antibodies to SARS-Cov-2 spike protein in nasal and oral mucosa, representing the frontline of host defense against COVID-19 infection, has been increasingly recognized as a key player in the acquired immunity.. Here we describe systemic and local antibody responses detected by Dual Path Platform (DPP) SARSCoV-2 IgM/IgG Assay during infection or after COVID-19 vaccine administration.. This rapid point-of-care test differentially detects circulating IgM and IgG antibodies to receptor-binding domain of SARS-CoV-2 spike protein in infected patients with diagnostic sensitivity ranging from 83 to 100 % (depending on the infection stage) at the specificity of 99–100 %. Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Blocking Assay:Article Title: Comparison of Three Commercial ELISA Kits for Detection of Antibodies Against SARS-CoV-2 in Serum Samples from Different Animal Species. Article Snippet: Both, the Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Integrated viral and immune monitoring in a prospective COVID-19 cohort from India. Article Snippet: In this study, we report on longitudinal kinetics of cellular immune subsets following SARS-CoV-2 infection in a cohort of hospitalized individuals and evaluate the interplay of these profiles with infecting viral variants, humoral immunity including neutralizing responses, vaccination history, and clinical outcomes.. A cohort of 121 SARS-CoV-2–infected individuals exhibiting varying disease states were prospectively evaluated for lymphopenic profiles, antiviral humoral responses and infecting viral variants for a period of up to 90 d spanning the period of February 2021 to January 2022 (second and third waves of infection).. A total of 51 participants received at least 1 vaccine dose of indigenous vaccines (Covishield or Covaxin) prior to recruitment. Article Title: Impaired immunogenicity after vaccination for SARS-CoV-2 in patients with gastrointestinal cancer: does tumor entity matter? Article Snippet: To identify the portion of SARS-CoV-2 NABs in relation to all antibodies [%], a blocking enzyme-linked immunosorbent assay ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines. Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: Rapid detection of systemic and mucosal antibody responses to COVID-19 infection or vaccination. Article Snippet: The presence of antibodies to SARS-Cov-2 spike protein in nasal and oral mucosa, representing the frontline of host defense against COVID-19 infection, has been increasingly recognized as a key player in the acquired immunity.. Here we describe systemic and local antibody responses detected by Dual Path Platform (DPP) SARSCoV-2 IgM/IgG Assay during infection or after COVID-19 vaccine administration.. This rapid point-of-care test differentially detects circulating IgM and IgG antibodies to receptor-binding domain of SARS-CoV-2 spike protein in infected patients with diagnostic sensitivity ranging from 83 to 100 % (depending on the infection stage) at the specificity of 99–100 %. Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: To speculate about neutralization—another functional parameter, we performed a correlation analysis to check if IgE data would correlate with neutralizing antibodies (NAbs) after natural infection and two vaccine doses from previously published data, using a surrogate neutralization assay based on an inhibition ELISA ( Article Title: An unexpected IgE anti-receptor binding domain response following natural infection and different types of SARS-CoV-2 vaccines Article Snippet: These data was obtained using a surrogate neutralization assay based on an inhibition ELISA ( |